Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) — The “India Cefoperazone Market, By Region, Competition, Forecast and Opportunities, 2020-2030F” report has been added to ResearchAndMarkets.com’s offering.
The India Cefoperazone Market was valued at USD 198.54 Million in 2024, and is expected to reach USD 271.68 Million by 2030, rising at a CAGR of 5.51%.
The India Cefoperazone market is witnessing steady growth due to rising demand for broad-spectrum antibiotics and increasing prevalence of bacterial infections. Cefoperazone, a third-generation cephalosporin antibiotic, is commonly used in the treatment of respiratory tract infections, urinary tract infections, skin infections, and intra-abdominal infections. Its combination with sulbactam has further enhanced its efficacy against beta-lactamase-producing organisms, making it a preferred choice among healthcare providers.
The growth of the Indian pharmaceutical industry, increasing healthcare awareness, and expanding hospital infrastructure are contributing to the market’s expansion. Government initiatives aimed at improving access to essential medicines, particularly in rural areas, also support the market. ALso, the rise in antimicrobial resistance is encouraging the use of more potent antibiotics like Cefoperazone-sulbactam combinations, especially in tertiary care hospitals. Several domestic pharmaceutical companies are actively manufacturing and marketing Cefoperazone and its combinations, contributing to competitive pricing and wider availability. The injectable form remains the most widely used due to its effectiveness in severe infections, especially in hospital settings.
Challenges such as regulatory compliance, quality concerns, and the growing threat of antibiotic resistance may hinder long-term growth. However, the emphasis on research and development, along with better stewardship practices, is expected to counterbalance these challenges. The India Cefoperazone market is poised for moderate yet sustainable growth, driven by its clinical effectiveness, increasing healthcare needs, and ongoing expansion of India’s healthcare infrastructure. The market will likely continue evolving in response to changing disease patterns and antibiotic prescribing practices.
Key Market Drivers
Rising Incidence of Bacterial Infections
The rising incidence of bacterial infections in India is a significant driver for the increasing demand for antibiotics such as Cefoperazone. A growing population, poor sanitation in certain regions, and overcrowding in urban areas contribute to the spread of infectious diseases. These infections often require broad-spectrum antibiotics for effective treatment, making Cefoperazone a vital option, especially in hospital and clinical settings.
India reports a high burden of lower respiratory tract infections, one of the major conditions treated with Cefoperazone. According to the Global Burden of Disease study, lower respiratory infections were responsible for over 400,000 deaths in India in 2023, making it one of the leading causes of mortality. Many of these cases require hospitalization and intravenous antibiotic therapy, areas where Cefoperazone is commonly administered.
Urinary tract infections (UTIs) are also on the rise in India, particularly among women and the elderly. As per data from the Indian Council of Medical Research (ICMR), nearly 33% of urinary tract infections in hospitals showed resistance to common antibiotics in 2023, necessitating the use of more potent drugs like Cefoperazone-sulbactam combinations.
With increasing antimicrobial resistance, physicians are opting for stronger antibiotic regimens to combat stubborn infections, especially those acquired in hospital environments. Cefoperazone’s broad-spectrum efficacy and effectiveness against beta-lactamase-producing organisms make it suitable for treating complicated bacterial infections. As the prevalence of such infections continues to grow, the demand for powerful, hospital-grade antibiotics like Cefoperazone is expected to rise, driving market expansion across India.
Key Market Challenges
Rising Antimicrobial Resistance
Rising antimicrobial resistance (AMR) in India is a serious public health concern and a critical challenge for the continued effectiveness of antibiotics like Cefoperazone. The misuse and overuse of antibiotics in both human health and agriculture have accelerated resistance among common bacterial strains. This growing resistance threatens to undermine the efficacy of broad-spectrum antibiotics that are vital in hospital-based treatments.
In 2023, data from the Indian Council of Medical Research (ICMR) revealed that over 57% of Klebsiella pneumoniae isolates showed resistance to third-generation cephalosporins, including Cefoperazone. This bacterium is a common cause of hospital-acquired infections, such as pneumonia and bloodstream infections. High resistance rates mean that physicians are often forced to prescribe stronger antibiotic combinations or shift to last-resort drugs, putting patients at greater risk and increasing treatment costs.
Another study conducted across tertiary care hospitals in India indicated that nearly 42% of Escherichia coli isolates were resistant to cephalosporins in 2023. This is especially concerning in urinary tract and abdominal infections, where Cefoperazone is commonly used. When standard antibiotics lose effectiveness, treatment becomes more complex and less predictable.
The rise in AMR reduces the therapeutic window for drugs like Cefoperazone and calls for immediate action in antibiotic stewardship. Hospitals are increasingly adopting combination therapies such as Cefoperazone-sulbactam to counter resistant organisms, but this is a temporary solution. Without stricter prescription controls, surveillance, and awareness, the market may see declining effectiveness of essential antibiotics, directly impacting patient care and public health outcomes in India.
Key Market Trends
Generic Availability and Price Competition
Generic availability and price competition play a major role in shaping the India Cefoperazone market. India’s well-established generic pharmaceutical industry enables wide-scale manufacturing and distribution of Cefoperazone and its combinations at affordable prices. This widespread generic availability increases access across both urban and rural healthcare settings, making the drug a preferred choice in hospital-based antibiotic therapies.
In 2023, over 80% of Cefoperazone sold in India came from generic brands, underscoring the dominance of local manufacturers in this segment. These generic formulations are produced by multiple Indian pharmaceutical companies, leading to intense price competition. The presence of numerous suppliers keeps prices low, benefiting government hospitals, private healthcare providers, and patients.
The price difference between branded and generic Cefoperazone can be significant. On average, generic Cefoperazone-Sulbactam injections are priced 30% to 50% lower than their branded counterparts in the Indian market. This price gap makes it easier for hospitals to procure antibiotics in bulk and prescribe them routinely in critical care settings, including for serious infections like sepsis and hospital-acquired pneumonia.
Cost-effectiveness is especially important in India’s public healthcare sector, where budgets are often constrained. The low cost of generics allows broader coverage in treatment protocols without compromising therapeutic efficacy. This environment of competitive pricing not only increases market penetration but also supports antibiotic stewardship by ensuring consistent supply. The dominance of generics and ongoing price competition are expected to continue driving volume growth in the Cefoperazone market while keeping the drug accessible across various levels of the healthcare system in India.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 70 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $198.54 Million |
| Forecasted Market Value (USD) by 2030 | $271.68 Million |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | India |
Report Scope:
Key Market Players
- Sterile India Private Ltd.
- Alkem Laboratories Ltd.
- Aurobindo Pharma Ltd.
- Bennet Pharmaceuticals Ltd.
- Tauras Laboratories Pvt. Ltd.
- Winsome Laboratories Ltd.
- Venus Remedies Ltd.
- Taj Pharmaceuticals Ltd.
- ELIS Pharmaceuticals (India) Pvt. Ltd.
- Cadila Pharmaceuticals Ltd.
India Cefoperazone Market, By Composition:
India Cefoperazone Market, By Route of Administration:
India Cefoperazone Market, By Source:
- In-house
- Contract Manufacturing Organizations
India Cefoperazone Market, By Distribution Channel:
India Cefoperazone Market, By Application:
- Bacterial Infections
- Respiratory Infections
- Skin Infections
- Urinary Infections
- Others
India Cefoperazone Market, By End User:
India Cefoperazone Market, By Region:
- North India
- East India
- West India
- South India
For more information about this report visit https://www.researchandmarkets.com/r/2ctgzf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Indian Cefoperazone Market
